The global organ transplant rejection medication market size was US$ 4.9 billion in 2022. The global market size is forecast to reach US$ 7 billion by 2031, growing at a compound annual growth rate (CAGR) of 3.9% during the forecast period from 2023 to 2031.
Immunosuppressive medications, often known as immunosuppressants, are pharmaceuticals used to suppress the immune system of organ transplant recipients to prevent organ rejection. When a person gets an organ donation, their immune system could label the new organ as alien and launch an attack. Immunosuppressive drugs are given to patients to assist in suppressing the immune system, lowering the risk of organ rejection, and enabling the transplanted organ to function normally.
Market Driving Factors
Due to the increased prevalence of chronic diseases, the organ transplantation rejection medication market is likely to expand throughout the forecast period. For instance, the HRSA 2022 update states that in the United States in 2021, more than 40,000 transplants were carried out. In addition, the national transplant waiting list currently has 105,842 persons on it, including men, women, and children.
Government partnerships, the opening of organ transplant facilities, and international campaigns to raise consumer knowledge of transplantation are all expected to spur market expansion since they boost product availability and foster competition. For instance, in September 2022, Cairo in the Middle East and Africa opened an organ transplant center in collaboration with foreign businesses. An automated database for transplants, patients, and donors is included in this organ transplant facility.
During the forecast period, an increase in the geriatric population is anticipated to drive the development of the global market. The requirement for health care rises as people get older because they are more susceptible to orthopedic ailments like osteoporosis, cardiovascular diseases like coronary heart disease, respiratory illnesses like TB and pneumonia, dental decay, and oral cancer. The target patient pool for organ transplants is probably going to get bigger as these diseases become more prevalent. By 2050, the number of elderly people worldwide is predicted to be over 2 billion (22% of the world's population).
The high cost of organ transplantation procedures and the limited supply of organs for transplantation may restrain the market. The cost of organ transplant surgeries is considerable, and patients may face significant financial hardships if they must take immunosuppressive drugs for the rest of their lives.
Market Segmentation Insights
By Drug Class Insights
In 2022, the calcineurin inhibitors segment held the highest global market share. During the projection period, the segment is projected to be driven by an increase in consumer preference for calcineurin inhibitors since they provide enough immunosuppression and have fewer side effects than other classes. The main factor influencing CNI utilization is how well they work to prevent acute organ transplant rejection.
By Transplant Type Insights
In 2022, the kidney transplant segment accounted for the highest market share. The most prevalent organ transplant procedure worldwide, with a high success rate, is kidney transplant. The number of kidney transplants conducted has increased due to the availability of living donors, including relatives and unrelated donors. The success and safety of kidney transplantation have increased due to developments in medical technology. The success rate of kidney transplants has increased owing to improved diagnostic equipment, new surgical methods, and immunosuppressive medications.
By Distribution Channel Insights
In 2022, the retail pharmacies market category held the highest market share. Due to their prompt availability and ease of use for purchasing prescriptions, retail pharmacies are preferred by many patients. During the projected period, the segment is likely to be driven by an increase in the number of patients choosing retail pharmacies because of the wide range of product brands that are offered at reduced prices.
Geographical Insights
North America is anticipated to account for a significant market share in the global market for organ transplant rejection medications. This growth is due to the large number of transplant surgeries, the rising frequency of chronic illnesses needing organ transplants, and the advantageous reimbursement policies in this region.
For instance, the kidney, liver, heart, lungs, pancreas, and intestines are the most frequently transplanted organs in the United States, according to the CDC 2022 update. According to the same source, bones, tendons, ligaments, skin, heart valves, blood arteries, and corneas are the most commonly transplanted tissues in the United States. Each year, around 3.3 million tissue grafts are given out. There were about 2.5 million grafts implanted.
The high incidence of chronic diseases in North America drives the industry. The market in the region is anticipated to grow during the projected period due to the quick uptake of cutting-edge treatment options in the healthcare industry for the treatment of various ailments.
List of Prominent Players
Segmentation Outline
The global organ transplant rejection medication market segmentation focuses on Drug Class, Transplant Type, Distribution Channel, and Region.
By Drug Class
By Transplant Type
By Distribution Channel
By Region
[TABLE OF CONTENTS]
1 INTRODUCTION OF GLOBAL ORGAN TRANSPLANT REJECTION MEDICATION MARKET
1.1 OVERVIEW OF THE MARKET
1.2 SCOPE OF REPORT
1.3 ASSUMPTIONS
2 EXECUTIVE SUMMARY: ORGAN TRANSPLANT REJECTION MEDICATION MARKET
3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 VALIDATION
3.3 PRIMARY INTERVIEWS
3.4 LIST OF DATA SOURCES
3.5 ANALYST TOOLS AND MODELS
4 GLOBAL ORGAN TRANSPLANT REJECTION MEDICATION MARKET OUTLOOK
4.1 OVERVIEW
4.2 MARKET DYNAMICS AND TRENDS
4.2.1 DRIVERS
4.2.2 RESTRAINTS
4.2.3 OPPORTUNITIES
4.3 PORTERS FIVE FORCE ANALYSIS
4.4 VALUE CHAIN ANALYSIS
4.5 MARKET GROWTH AND OUTLOOK
4.5.1 PRICE TREND ANALYSIS
4.5.2 OPPORTUNITY SHARE
5 GLOBAL ORGAN TRANSPLANT REJECTION MEDICATION MARKET, BY DRUG CLASS
5.1 OVERVIEW
5.2 ANTIBODIES
5.3 ANTIMETABOLITES
5.4 CALCINEURIN INHIBITORS
5.5 MTOR INHIBITORS
5.6 STEROIDS
6 GLOBAL ORGAN TRANSPLANT REJECTION MEDICATION MARKET, BY TRANSPLANT TYPE
6.1 OVERVIEW
6.2 KIDNEY
6.3 LIVER
6.4 HEART
6.5 LUNG
6.6 PANCREAS
6.7 OTHERS
7 GLOBAL ORGAN TRANSPLANT REJECTION MEDICATION MARKET, BY DISTRIBUTION CHANNEL
7.1 OVERVIEW
7.2 HOSPITALS PHARMACIES
7.3 RETAIL PHARMACIES
7.4 ONLINE PHARMACIES
8 GLOBAL ORGAN TRANSPLANT REJECTION MEDICATION MARKET, BY GEOGRAPHY
8.1 OVERVIEW
8.2 NORTH AMERICA
8.2.1 NORTH AMERICA MARKET SNAPSHOT
8.2.2 U.S.
8.2.3 CANADA
8.2.4 MEXICO
8.3 EUROPE
8.3.1 EUROPE MARKET SNAPSHOT
8.3.2 WESTERN EUROPE
8.3.2.1 THE UK
8.3.2.2 GERMANY
8.3.2.3 FRANCE
8.3.2.4 ITALY
8.3.2.5 SPAIN
8.3.2.6 REST OF WESTERN EUROPE
8.3.3 EASTERN EUROPE
8.3.3. 1 POLAND
8.3.3.2 RUSSIA
8.3.3.3 REST OF EASTERN EUROPE
8.4 ASIA PACIFIC
8.4.1 ASIA PACIFIC MARKET SNAPSHOT
8.4.2 CHINA
8.4.3 JAPAN
8.4.4 INDIA
8.4.5 AUSTRALIA & NEW ZEALAND
8.4.6 ASEAN
8.4.7 REST OF ASIA PACIFIC
8.5 MIDDLE EAST & AFRICA
8.5.1 MIDDLE EAST & AFRICA MARKET SNAPSHOT
8.5.2 UAE
8.5.3 SAUDI ARABIA
8.5.4 SOUTH AFRICA
8.5.5 REST OF MEA
8.6 SOUTH AMERICA
8.6.1 SOUTH AMERICA MARKET SNAPSHOT
8.6.2 BRAZIL
8.6.3 ARGENTINA
8.6.4 REST OF SOUTH AMERICA
9 GLOBAL ORGAN TRANSPLANT REJECTION MEDICATION MARKET COMPETITIVE LANDSCAPE
9.1 OVERVIEW
9.2 COMPANY MARKET RANKING
9.3 KEY DEVELOPMENT STRATEGIES
9.4 COMPETITIVE DASHBOARD
9.5 PRODUCT MAPPING
9.6 TOP PLAYER POSITIONING, 2022
9.7 COMPETITIVE HEATMAP
9.8 TOP WINNING STRATEGIES
10 COMPANY PROFILES
10.1 PFIZER, INC.
10.1.1 OVERVIEW
10.1.2 FINANCIAL PERFORMANCE
10.1.3 PRODUCT OUTLOOK
10.1.4 KEY DEVELOPMENTS
10.1.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.2 ASTELLAS PHARMA, INC.
10.2.1 OVERVIEW
10.2.2 FINANCIAL PERFORMANCE
10.2.3 PRODUCT OUTLOOK
10.2.4 KEY DEVELOPMENTS
10.2.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.3 NOVARTIS AG
10.3.1 OVERVIEW
10.3.2 FINANCIAL PERFORMANCE
10.3.3 PRODUCT OUTLOOK
10.3.4 KEY DEVELOPMENTS
10.3.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.4 F. HOFFMANN-LA ROCHE LTD.
10.4.1 OVERVIEW
10.4.2 FINANCIAL PERFORMANCE
10.4.3 PRODUCT OUTLOOK
10.4.4 KEY DEVELOPMENTS
10.4.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.5 SANOFI
10.5.1 OVERVIEW
10.5.2 FINANCIAL PERFORMANCE
10.5.3 PRODUCT OUTLOOK
10.5.4 KEY DEVELOPMENTS
10.5.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.6 BRISTOL-MYERS SQUIBB COMPANY
10.6.1 OVERVIEW
10.6.2 FINANCIAL PERFORMANCE
10.6.3 PRODUCT OUTLOOK
10.6.4 KEY DEVELOPMENTS
10.6.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.7 GLAXOSMITHKLINE PLC
10.7.1 OVERVIEW
10.7.2 FINANCIAL PERFORMANCE
10.7.3 PRODUCT OUTLOOK
10.7.4 KEY DEVELOPMENTS
10.7.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.8 ABBVIE, INC.
10.8.1 OVERVIEW
10.8.2 FINANCIAL PERFORMANCE
10.8.3 PRODUCT OUTLOOK
10.8.4 KEY DEVELOPMENTS
10.8.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.9 HANSA BIOPHARMA
10.9.1 OVERVIEW
10.9.2 FINANCIAL PERFORMANCE
10.9.3 PRODUCT OUTLOOK
10.9.4 KEY DEVELOPMENTS
10.9.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.10 WOCKHARDT
10.10.1 OVERVIEW
10.10.2 FINANCIAL PERFORMANCE
10.10.3 PRODUCT OUTLOOK
10.10.4 KEY DEVELOPMENTS
10.10.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.11 VIATRIS, INC.
10.11.1 OVERVIEW
10.11.2 FINANCIAL PERFORMANCE
10.11.3 PRODUCT OUTLOOK
10.11.4 KEY DEVELOPMENTS
10.11.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.12 GLENMARK
10.12.1 OVERVIEW
10.12.2 FINANCIAL PERFORMANCE
10.12.3 PRODUCT OUTLOOK
10.12.4 KEY DEVELOPMENTS
10.12.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.13 BIOCON
10.13.1 OVERVIEW
10.13.2 FINANCIAL PERFORMANCE
10.13.3 PRODUCT OUTLOOK
10.13.4 KEY DEVELOPMENTS
10.13.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.14 HIKMA PHARMACEUTICALS PLC
10.14.1 OVERVIEW
10.14.2 FINANCIAL PERFORMANCE
10.14.3 PRODUCT OUTLOOK
10.14.4 KEY DEVELOPMENTS
10.14.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.15 TEVA PHARMACEUTICAL U.S.A INC.
10.15.1 OVERVIEW
10.15.2 FINANCIAL PERFORMANCE
10.15.3 PRODUCT OUTLOOK
10.15.4 KEY DEVELOPMENTS
10.15.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.16 ZYDUS PHARMACEUTICALS, INC.
10.16.1 OVERVIEW
10.16.2 FINANCIAL PERFORMANCE
10.16.3 PRODUCT OUTLOOK
10.16.4 KEY DEVELOPMENTS
10.16.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
01
お客様のニーズに合わせてレポートをカスタマイズ可能
02
ベテランの市場調査員による専門的な分析
03
安全で簡単に利用できるオンライン決済方法
04
お客様のご要望に応じて、特定の章を購入することができます。
05
すべてのレポートに専門的な日本語翻訳を提供
06
包括的でわかりやすいレポートを迅速にお届けします。
07
購入後も継続的なサポートとアップデートが受けられます。
We Accept
Copyright ©2022 All rights reserved